Methylprednisolone, used in conjunction with tocilizumab and lopinavir therapy, has shown promise in the treatment of SARS-CoV-2 infection through decreased oxygen requirements, decrease in C-reactive protein, increased lymphocyte levels, decreased fever, and improved chest tightness, potentially related to depression of inflammatory cytokine involvement [61]. Here, CRP is linked to depressive disorder.